185 related articles for article (PubMed ID: 15984343)
61. Env-specific CTL predominate in cats protected from feline immunodeficiency virus infection by vaccination.
Flynn JN; Keating P; Hosie MJ; Mackett M; Stephens EB; Beatty JA; Neil JC; Jarrett O
J Immunol; 1996 Oct; 157(8):3658-65. PubMed ID: 8871667
[TBL] [Abstract][Full Text] [Related]
62. Tumor necrosis factor alpha levels in cats experimentally infected with feline immunodeficiency virus: effects of immunization and feline leukemia virus infection.
Lehmann R; Joller H; Haagmans BL; Lutz H
Vet Immunol Immunopathol; 1992 Dec; 35(1-2):61-9. PubMed ID: 1337403
[TBL] [Abstract][Full Text] [Related]
63. Protection against feline leukemia virus infection by use of an inactivated virus vaccine.
Hoover EA; Perigo NA; Quackenbush SL; Mathiason-DuBard CK; Overbaugh JM; Kloetzer WS; Elder JH; Mullins JI
J Am Vet Med Assoc; 1991 Nov; 199(10):1392-401. PubMed ID: 1666090
[TBL] [Abstract][Full Text] [Related]
64. Evaluation of vaccination strategies against infection with feline immunodeficiency virus (FIV) based on recombinant viral vectors expressing FIV Rev and OrfA.
Huisman W; Schrauwen EJ; Tijhaar E; Süzer Y; Pas SD; van Amerongen G; Sutter G; Rimmelzwaan GF; Osterhaus AD
Vet Immunol Immunopathol; 2008 Dec; 126(3-4):332-8. PubMed ID: 18952300
[TBL] [Abstract][Full Text] [Related]
65. Prime-boost vaccination using DNA and whole inactivated virus vaccines provides limited protection against virulent feline immunodeficiency virus.
Dunham SP; Bruce J; Klein D; Flynn JN; Golder MC; MacDonald S; Jarrett O; Neil JC
Vaccine; 2006 Nov; 24(49-50):7095-108. PubMed ID: 17049683
[TBL] [Abstract][Full Text] [Related]
66. Determining the feline immunodeficiency virus (FIV) status of FIV-vaccinated cats using point-of-care antibody kits.
Westman ME; Malik R; Hall E; Sheehy PA; Norris JM
Comp Immunol Microbiol Infect Dis; 2015 Oct; 42():43-52. PubMed ID: 26459979
[TBL] [Abstract][Full Text] [Related]
67. Evaluation of efficacy and safety of an inactivated virus vaccine against feline leukemia virus infection.
Hines DL; Cutting JA; Dietrich DL; Walsh JA
J Am Vet Med Assoc; 1991 Nov; 199(10):1428-30. PubMed ID: 1666097
[TBL] [Abstract][Full Text] [Related]
68. Targeted lymph node immunization can protect cats from a mucosal challenge with feline immunodeficiency virus.
Finerty S; Stokes CR; Gruffydd-Jones TJ; Hillman TJ; Barr FJ; Harbour DA
Vaccine; 2001 Oct; 20(1-2):49-58. PubMed ID: 11567745
[TBL] [Abstract][Full Text] [Related]
69. Simian and feline immunodeficiency viruses: animal lentivirus models for evaluation of AIDS vaccines and antiviral agents.
Gardner MB
Antiviral Res; 1991 May; 15(4):267-86. PubMed ID: 1659310
[TBL] [Abstract][Full Text] [Related]
70. Vaccine protection against feline immunodeficiency virus: setting the challenge.
Zwijnenberg R; Yamamoto JK
Aust Vet J; 2007 Jun; 85(6):210-1. PubMed ID: 17547630
[No Abstract] [Full Text] [Related]
71. Deluge of questions prompts AAFP to develop FIV vaccine brief. American Association of Feline Practitioners.
Kahler SC;
J Am Vet Med Assoc; 2002 Nov; 221(9):1231-4. PubMed ID: 12418682
[No Abstract] [Full Text] [Related]
72. Salmonella typhimurium aroA recombinants and immune-stimulating complexes as vaccine candidates for feline immunodeficiency virus.
Tijhaar EJ; Huisman W; Huisman RC; Siebelink KH; Karlas JA; de Ronde A; van Herwijnen R; Mooi FR; Osterhaus AD
J Gen Virol; 1997 Dec; 78 ( Pt 12)():3265-75. PubMed ID: 9400977
[TBL] [Abstract][Full Text] [Related]
73. DNA vaccination using expression vectors carrying FIV structural genes induces immune response against feline immunodeficiency virus.
Cuisinier AM; Mallet V; Meyer A; Caldora C; Aubert A
Vaccine; 1997 Jul; 15(10):1085-94. PubMed ID: 9269051
[TBL] [Abstract][Full Text] [Related]
74. Effect of vaccination against feline immunodeficiency virus on results of serologic testing in cats.
Levy JK; Crawford PC; Slater MR
J Am Vet Med Assoc; 2004 Nov; 225(10):1558-61. PubMed ID: 15568388
[TBL] [Abstract][Full Text] [Related]
75. Protection of neonatal kittens against feline immunodeficiency virus infection with passive maternal antiviral antibodies.
Pu R; Okada S; Little ER; Xu B; Stoffs WV; Yamamoto JK
AIDS; 1995 Mar; 9(3):235-42. PubMed ID: 7755911
[TBL] [Abstract][Full Text] [Related]
76. Feline immunodeficiency virus vaccine: a rational paradigm for clinical decision-making.
Zislin A
Biologicals; 2005 Dec; 33(4):219-20. PubMed ID: 16257537
[TBL] [Abstract][Full Text] [Related]
77. AIDS vaccination studies using an ex vivo feline immunodeficiency virus model: protection from an intraclade challenge administered systemically or mucosally by an attenuated vaccine.
Pistello M; Matteucci D; Bonci F; Isola P; Mazzetti P; Zaccaro L; Merico A; Del Mauro D; Flynn N; Bendinelli M
J Virol; 2003 Oct; 77(20):10740-50. PubMed ID: 14512524
[TBL] [Abstract][Full Text] [Related]
78. Perspectives on FIV vaccine development.
Elyar JS; Tellier MC; Soos JM; Yamamoto JK
Vaccine; 1997; 15(12-13):1437-44. PubMed ID: 9302758
[TBL] [Abstract][Full Text] [Related]
79. Pre-existing immunity to pathogenic Listeria monocytogenes does not prevent induction of immune responses to feline immunodeficiency virus by a novel recombinant Listeria monocytogenes vaccine.
Stevens R; Lavoy A; Nordone S; Burkhard M; Dean GA
Vaccine; 2005 Feb; 23(12):1479-90. PubMed ID: 15670884
[TBL] [Abstract][Full Text] [Related]
80. Feline leukaemia virus (FeLV) and feline immunodeficiency virus infections in cats in the Pisa district of Tuscany, and attempts to control FeLV infection in a colony of domestic cats by vaccination.
Bandecchi P; Dell'Omodarme M; Magi M; Palamidessi A; Prati MC
Vet Rec; 2006 Apr; 158(16):555-7. PubMed ID: 16632529
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
